Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced that it has signed an exclusive three-year distribution agreement with Mistaire to distribute the Company's Urine HIV-1 EIA and Western Blot test kits in the six member states of the Gulf Cooperative Council (GCC)
The company will have distribution rights in Saudi Arabia, the United Arab Emirates (UAE), Bahrain, Qatar, Kuwait, and Oman. The agreement also gives Mistaire non-exclusive distribution rights for the Serum HIV-1 Western Blot tests in the same territories.
The agreement calls for minimum purchase orders of Calypte's products, and assuming that business activities in the Gulf region return to normalcy shortly, Mistaire's initial order is likely to be placed and shipped before the end of the current quarter. The agreement is extendable for an additional two years contingent upon the distributor's performance, and new minimum purchases will be negotiated at that time.
US-based Calypte Biomedical Corporation is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. — (menareport.com)
© 2003 Mena Report (www.menareport.com)
